Evidence map›Paper›PMID 42170586›Full record

ArticleJournal of human immunity2025

Treatment of severe refractory immune neutropenia with ruxolitinib: Two cases.

Richard Schwarzkopf, Andrew A Y Chen, Stephanie Quon, Julia Varghese, Janet Roberts, Richard K Wood, Luke Y C Chen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of human immunity, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Richard Schwarzkopf *Department of Psychology and Neuroscience, Dalhousie University, Halifax, Canada.ORCID https://orcid.org/0009-0009-4926-8298
Andrew A Y Chen *Department of Biochemistry and Molecular Biology, Dalhousie University, Halifax, Canada.ORCID https://orcid.org/0009-0006-8899-9059
Stephanie QuonFaculty of Medicine, University of British Columbia, Vancouver, Canada.ORCID https://orcid.org/0000-0001-9188-8380
Julia VargheseDivision of Hematology, University of British Columbia, Vancouver, Canada.ORCID https://orcid.org/0000-0002-4424-634X
Janet RobertsDivision of Rheumatology, Department of Medicine, Dalhousie University, Halifax, Canada.ORCID https://orcid.org/0000-0002-3787-8541
Richard K WoodDepartment of Pathology, Dalhousie University, Halifax, Canada.ORCID https://orcid.org/0000-0002-2523-890X
Luke Y C ChenDivision of Hematology, University of British Columbia, Vancouver, Canada.ORCID https://orcid.org/0000-0002-9551-2951

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Two adult patients with severe immune neutropenia refractory to standard therapies achieved durable remission following treatment with the JAK inhibitor ruxolitinib. This report highlights the potential of JAK-STAT pathway inhibition for managing G-CSF and steroid-refractory immune-mediated neutropenia.

Identifiers

PMID42170586
PMCPMC13177604

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.